Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRVS Stock Price Chart Interactive Chart >
CRVS Price/Volume Stats
| Current price | $0.86 | 52-week high | $2.17 |
| Prev. close | $0.84 | 52-week low | $0.70 |
| Day low | $0.82 | Volume | 47,000 |
| Day high | $0.87 | Avg. volume | 110,896 |
| 50-day MA | $0.87 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 40.22M |
Corvus Pharmaceuticals, Inc. (CRVS) Company Bio
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.
Latest CRVS News From Around the Web
Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And MoreThe Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Intellicheck The Trade: Intellicheck, Inc. (NASDAQ: IDN ) President Garrett Gafke bought a total of 2,000 shares at an average price of $2.01. To acquire these shares, it cost around $4.02 thousand. What’s Happening: The company’s stock dipped around 43% over the past six months. What Intelliche... |
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionResults in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE N |
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, along with an update |
James Rosenbaum Presented the Distinguished Service Award by the American College of RheumatologyBURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November 12, 2022. Dr. Rosenbaum received the ACR’s second highest honor, for his outstanding contributions to rheumatology and care of patients. Founded in 1934, the ACR is a not-for-profit, professional ass |
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CRVS) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea… |
CRVS Price Returns
| 1-mo | 0.15% |
| 3-mo | 1.27% |
| 6-mo | -1.15% |
| 1-year | -53.01% |
| 3-year | -83.52% |
| 5-year | -89.45% |
| YTD | 1.18% |
| 2022 | -64.73% |
| 2021 | -32.30% |
| 2020 | -34.56% |
| 2019 | 48.23% |
| 2018 | -64.58% |
Loading social stream, please wait...